谁将从二甲双胍中受益？

{"title":"谁将从二甲双胍中受益？","authors":"J. Mortimer, V. Seewaldt","doi":"10.1001/jamaoncol.2022.1911","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":" ","pages":""},"PeriodicalIF":22.5000,"publicationDate":"2022-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Who Will Benefit From Metformin?\",\"authors\":\"J. Mortimer, V. Seewaldt\",\"doi\":\"10.1001/jamaoncol.2022.1911\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":14850,\"journal\":{\"name\":\"JAMA Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":22.5000,\"publicationDate\":\"2022-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jamaoncol.2022.1911\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoncol.2022.1911","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}